Purinergic signaling elements are correlated with coagulation players in peripheral blood and leukocyte samples from COVID-19 patients, 2022, Schultz

Discussion in 'Epidemics (including Covid-19, not Long Covid)' started by Andy, Feb 1, 2022.

  1. Andy

    Andy Committee Member

    Messages:
    22,309
    Location:
    Hampshire, UK
    Abstract

    For over a year, the coronavirus disease 2019 has been affecting the world population by causing severe tissue injuries and death in infected people. Adenosine triphosphate (ATP) and the nicotinamide adenine dinucleotide (NAD +) are two molecules that are released into the extracellular microenvironment after direct virus infection or cell death caused by hyper inflammation and coagulopathy. Also, these molecules are well known to participate in multiple pathways and have a pivotal role in the purinergic signaling pathway. Thus, using public datasets available on the Gene Expression Omnibus (GEO), we analyzed raw proteomics data acquired using mass spectrometry (the gold standard method) and raw genomics data from COVID-19 patient samples obtained by microarray. The data was analyzed using bioinformatics and statistical methods according to our objectives.

    Here, we compared the purinergic profile of the total leukocyte population and evaluated the levels of these soluble biomolecules in the blood, and their correlation with coagulation components in COVID-19 patients, in comparison to healthy people or non-COVID-19 patients. The blood metabolite analysis showed a stage-dependent inosine increase in COVID-19 patients, while the nucleotides ATP and ADP had positive correlations with fibrinogen and other coagulation proteins. Also, ATP, ADP, inosine, and hypoxanthine had positive and negative correlations with clinical features. Regarding leukocyte gene expression, COVID-19 patients showed an upregulation of the P2RX1, P2RX4, P2RX5, P2RX7, P2RY1, P2RY12, PANX1, ADORA2B, NLPR3, and F3 genes. Yet, the ectoenzymes of the canonical and non-canonical adenosinergic pathway (ENTPD1 and CD38) are upregulated, suggesting that adenosine is produced by both active adenosinergic pathways. Hence, approaches targeting these biomolecules or their specific purinoreceptors and ectoenzymes may attenuate the high inflammatory state and the coagulopathy seen in COVID-19 patients.

    Key messages
    • Adenosinergic pathways are modulated on leukocytes from COVID-19 patients.

    • Plasmatic inosine levels are increased in COVID-19 patients.

    • ATP, ADP, AMP, hypoxanthine, and inosine are correlated with coagulation players.

    • The nucleotides and nucleosides are correlated with patients’ clinical features.

    • The P2 receptors and ectoenzymes are correlated with Tissue factor in COVID-19.
    Open access, https://link.springer.com/article/10.1007/s00109-021-02175-y
     

Share This Page